HERTRAZ 440 MG INJ. VIAL.

About

HERTRAZ 440 MG INJ. VIAL. is a targeted biological therapy containing trastuzumab, a recombinant humanized monoclonal antibody that specifically binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a proto-oncogene that, when overexpressed, plays a critical role in the growth and proliferation of certain aggressive cancers, particularly breast and gastric cancers. By binding to HER2, trastuzumab inhibits downstream signaling pathways, leading to cell cycle arrest and apoptosis in HER2-overexpressing tumor cells. It also mediates antibody-dependent cell-mediated cytotoxicity (ADCC), recruiting immune cells to destroy cancer cells. This targeted approach makes Hertraz a highly effective treatment for HER2-positive malignancies, often used in combination with chemotherapy or as monotherapy, significantly improving patient outcomes.

Uses

• Treatment of HER2-positive early breast cancer.
• Management of HER2-positive metastatic breast cancer.
• Therapy for HER2-positive metastatic gastric cancer.
• Adjuvant therapy after surgery for early breast cancer.

Directions For Use

Administer intravenously under the supervision of a qualified oncologist. Dosage and infusion schedule are determined by the patient's body weight and treatment protocol.

Benefits

• Targets HER2-overexpressing cancer cells.
• Inhibits tumor cell growth and proliferation.
• Improves disease-free and overall survival.
• Often used in combination with chemotherapy.
• Effective against aggressive HER2-positive cancers.
• Mediates immune-mediated destruction of cancer cells.

Side Effects

• Cardiotoxicity (heart failure, decreased ejection fraction)
• Infusion-related reactions (fever, chills, nausea)
• Diarrhea
• Nausea
• Fatigue
• Headache
• Rash
• Myelosuppression (rare)
• Peripheral neuropathy
• Muscle pain
• Abdominal pain
• Cough

Safety Measures

• Alcohol - No specific interaction, but alcohol should be avoided due to general health considerations during cancer treatment.
• Pregnancy - Contraindicated during pregnancy due to severe fetal harm risk; effective contraception is essential.
• Breastfeeding - Contraindicated during breastfeeding; discontinue breastfeeding due to potential harm to the infant.
• Liver - Use with caution in patients with severe liver impairment; monitor liver function.
• Kidney - Use with caution in patients with severe renal impairment; monitor renal function.
• Lung - Monitor for pulmonary toxicity, including interstitial pneumonitis; report any new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.